The relation of CD4 + CD25+Foxp3+ regulatory T cells concentration with disease activity and damage index in systemic lupus erythematosus

Abstract

Introduction

Regulatory T cells (Treg) deficits, both quantitative and qualitative, are known to be possible triggers for the development of autoimmune disorders by causing T and B cells dysfunction. The contribution of Treg deficiency in the etiology of systemic lupus erythematosus (SLE) is still being debated. The aim of the present study is to evaluate the percentage of circulating CD4⁺CD25⁺Foxp3⁺ Treg cells in a cohort of Egyptian SLE patients and to correlate this value with the activity and damage index of these patients.

Methods

50 female patients with SLE together with an equal number of age- and sex-matched healthy controls were enrolled in the study. Flow cytometric determination of peripheral Treg cells was carried out for all participants by detecting the percentage of CD4⁺CD25+Foxp3+ cells to compare cases with the control group. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), while disease damage was assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI). Both indices were correlated with the percentage of CD4⁺CD25⁺Foxp3 T regulatory cells.

Results

CD4⁺CD25⁺Foxp3⁺ Treg cells percentage was significantly decreased in patients with SLE as compared to healthy controls. On correlating CD4⁺CD25⁺Foxp3⁺ Treg percentage with SLEDAI-2K, a significantly negative correlation was found. Also, there was a negative significant correlation between CD4⁺CD25⁺Foxp3⁺ Treg cells percentage and SLICC/ACR DI. On correlating SLEDAI-2K with damage index (SLICC/ACR DI), we found highly significant positive correlation.

Conclusion

Our study showed impaired production of CD4⁺CD25⁺Foxp3⁺ Tregs in SLE patients, which can play a reciprocal role with some cytokines to affect the activity of the disease and organ damage. CD4⁺CD25⁺Foxp3⁺ Tregs cells should be the target to determine the clinical effectiveness of new therapy to modulate Tregs besides the traditional treatments.

Keywords

Systemic lupus erythematosus t regulatory cells forkhead box p3 CD4 CD25 SLEDAI-2K

Get full access to this article

View all access options for this article.

References

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121.

Picchianti-Diamanti

Rosado

Scarsella

Lagana

`and D’Amelio

. P-glycoprotein and drug resistance in systemic autoimmune diseases. Intern J Mol Sci 2014; 15: 4965–4976.

Miyara

Ito

Sakaguchi

. TREG-cell therapies for autoimmune rheumatic diseases. Nature Rev Rheumato 2014; 10: 543–551.

Miyara

Gorochov

Ehrenstaein

Musset

Sakaguchi

Amoura

. Human Foxp3+ regulatory T cells in systemic autoimmune diseases. Autoimmune Rev 2011; 10: 744–755.

Tao

Cheng

Tang

Liu

Pan

. Foxp3, regulatory T cell and autoimmune diseases. Inflammation 2017; 40: 328–339.

Costa

Marques

Godinho

, et al. Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives. Clin Exp Immunol 2017; 189: 318–330.

Cai

Luo

Lin

, et al. Expression and significance of Th17 and Treg cells in peripheral blood of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2012; 92: 460–463.

Zhao

Jiang

, et al. Imbalance of different types of CD4 forkhead box protein 3 (Foxp3) T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol 2013; 174: 345–355.

Xing

Wang

, et al. Elevated Th17 cells are accompanied by Foxp3? Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012; 32: 949–958.

10.

Yates

Whittington

Mitchell

Lechler

Lightstone

Lombardi

. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008; 153: 44–55.

11.

Azab

Bassyouni

Emad

Abd El-Wahab

Hamdy

Mashahit

. CD4 +CD25+regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008; 127: 151–157.

12.

Yan

Chen

Kuang

Shen

Chen

. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 2008; 58: 801–812.

13.

Banham

. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3 (+) regulatory T cells. Trends Immunol 2006; 27: 541–544.

14.

Liu

Kao

Manzi

Ahearn

. Biomarkers in systemic lupus erythematosus: Challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013; 5: 210.

15.

Petri

Orbai

Alarcón

, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. ArthritisRheum 2012; 64: 2677–2686.

16.

Gladman

Ibañez

Urowitz

. Systemic lupus erythematosus disease activity index 2000, J Rheumatol 2002; 29: 288–291.

17.

Gladman

Ginzler

Goldsmith

, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

18.

Choi

Kim

Craft

. The pathogenesis of systemic lupus erythematosus: An update. Curr Opin Immunol. 2012; 24: 651.

19.

Nabil Rafat

Abdelwahab

Mamdouh

Mahmoud

Farag

Marwan

. Study of regulatory T – cells in systemic lupus erythematosus and rheumatoid arthritis. Nat Sci 2018; 16: 38–48.

20.

Lee

Hong

Yun

Kim

Yoo

. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheuma (Oxford) 2008; 47: 789–794.

21.

Atfy

Amr

Elnaggar

, et al. Impact of CD4+CD25high regulatory T-cells and Foxp3 expression in the peripheral blood of patients with systemic lupus erythematosus. Egyptian J Immuno 2009; 16: 117–126.

22.

Barâth

Solt

SZ P

Kiss

, et al. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+ CD25highFoxp3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 2007; 40: 521–528.

23.

Maher

Taha

Hozayn

, et al. Study of balance between T-helper 17 /T-regulatory cells in systemic lupus erythematosus and its relation to disease activity. Curr Pediatr Res 2019; 23: 49–55.

24.

El-Maraghy

Ghaly

Dessouki

Nasef

Metwally

. CD4+CD25-Foxp3+ T cells as a marker of disease activity and organ damage in systemic lupus erythematosus patients. Arch Med Sci. 2018; 14: 1033–1040.

25.

Bonelli

Göschl

Blüml

, et al.

CD4+ CD25-Foxp3+ T cells: A marker for lupus nephritis?

Arthritis Res Ther 2014; 16: 104.

26.

Santhanam

Mani

Tamilselvam

Sankaralingam

. ESR, uric acid and its correlation with disease activity in SLE - Is it myth or reality! Indian Rheumatology Association 2015; 10: 112–113.

27.

Mirzayan

Schmidt

Witte

. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatol (Oxford) 2000; 39: 1316–1319.

28.

Chang

Abrahamowicz

Ferland

Fortin

. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients or physicians evaluations of recent lupus activity. J Rheumatol 2002; 29: 2350–2358.

29.

Bruce

O'Keeffe

Farewell

, et al.

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the

Sys Lupus Intern Collab Clin (SLICC) Incep Cohort Annals Rheu Dis 2015; 74: 1706–1713.

30.

Ghazali

WSW

Daud

SMM

Mohammad

Wong

. SLICC damage index score in systemic lupus erythematosus patients and its associated factors. Medicine 2018; 97: 12787.